ANVS · XBRL financial data

Annovis Bio financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANVS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	0	0	0	0	0
Research and development	3,054	8,479	16,516	38,791	19,995	25,216
General and administrative	3,586	6,058	8,996	6,244	6,699	4,480
Total operating expenses	6,640	14,537	25,511	45,035	26,695	29,695
Operating income (loss)	(6,640)	(14,537)	(25,511)	(45,035)	(26,695)	(29,695)
Interest income	—	—	—	668	332	699
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(5,462)	(14,487)	(25,329)	(56,204)	(24,590)	(28,854)
Earnings per share, basic USD per share	(0.87)	(1.90)	(3.10)	(6.23)	(2.02)	(1.40)
Earnings per share, diluted USD per share	(0.87)	(1.90)	(3.10)	(6.23)	(2.31)	(1.40)
Weighted average shares, basic thousands of shares	6,309	7,626	8,162	9,023	12,182	20,552
Weighted average shares, diluted thousands of shares	6,309	7,626	8,162	9,023	12,235	20,552

Fiscal years (ANVS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	8,075	45,686	28,378	5,755	10,552	19,532
Total current assets	8,119	46,001	36,022	10,208	—	—
Total assets	8,119	46,001	36,022	10,208	13,926	21,082
Accounts payable	342	688	3,961	1,293	2,306	2,591
Total current liabilities	578	1,507	7,699	4,279	3,881	3,635
Total liabilities	578	1,507	7,699	17,959	4,618	4,230
Accumulated deficit	(14,239)	(28,726)	(54,055)	(110,259)	(134,849)	(163,704)
Total stockholders' equity	7,541	44,495	28,324	(7,751)	9,308	16,851
Total liabilities and equity	8,119	46,001	36,022	10,208	13,926	21,082
Common shares outstanding (cover page) thousands of shares	6,947	8,164	8,217	11,011	19,486	28,355

Fiscal years (ANVS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(5,462)	(14,487)	(25,329)	(56,204)	(24,590)	(28,854)
Stock-based compensation	1,865	4,698	9,153	4,628	3,837	1,798
Net cash from operating activities	(3,971)	(9,132)	(17,313)	(39,967)	(21,895)	(25,620)
Proceeds from issuing common stock	12,034	46,648	—	16,886	18,667	—
Net cash from financing activities	12,044	46,744	5	17,344	26,692	34,600
Net change in cash	8,073	37,611	(17,308)	(22,623)	4,797	8,980

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Annovis Bio	18,729	0*	(21,914)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	54,980	33,432	(24,931)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
BriaCell Therapeutics	9,852	not reported	(5,959)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.